---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-014351"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:38:03.110726+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives

## Summary
- Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.
- G&A expenses rose to $3.3M from $1.5M on pre-commercial launch costs for LYMPHIR.
- Engaged Jefferies as exclusive financial advisor to evaluate strategic alternatives; active discussions underway.
- Received permanent J-code J9161 for LYMPHIR effective April 1, 2025; launch on track for H1 2025.
- R&D expenses were $1.3M, up from $1.2M, supporting two investigator-initiated trials.

## SEC filing metadata
- accession: 0001213900-25-014351
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025014351/0001213900-25-014351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025014351/ea0231246-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-014351
- JSON: https://secwatch.observer/filing/0001213900-25-014351.json
- Plain text: https://secwatch.observer/filing/0001213900-25-014351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.